Source comparison
Tesamorelin + Ipamorelin Blend Review 2026: Peptide Comparison
The following table compares the tesamorelin + ipamorelin blend against commonly utilized alternatives in growth hormone research applications, highlighting receptor mechanisms, half-life characteristics, and observed outcomes from peer-reviewed studies publis
This comparison does not assign a generated winner or score.
- The following table compares the tesamorelin + ipamorelin blend against commonly utilized alternatives in growth hormone research applications, highlighting receptor mechanisms, half-life characteristics, and observed outcomes from peer-reviewed studies published through 2026.
- Tesamorelin + Ipamorelin
- GHRH-R + GHS-R1a (dual pathway)
- 26–38 min (Tes) / 2 hours (Ipa)
- 240–310%
- Minimal (<10% cortisol increase)
- Superior synergy through independent receptor pathways; most consistent pulsatile GH profile in current research
- Tesamorelin alone
- GHRH-R (pituitary somatotrophs)
- 26–38 minutes
- 120–150%
- None
- Effective GHRH analog but limited by endogenous somatostatin tone; benefits plateau without ghrelin pathway activation
- Ipamorelin alone
- GHS-R1a (ghrelin receptor)
- 2 hours
- 140–180%
- Minimal (<5% cortisol increase)
- Longest half-life of pentapeptide ghrelin mimetics; strong safety profile but ceiling effect without GHRH co-stimulation
- CJC-1295 + Ipamorelin
- 6–8 days (CJC) / 2 hours (Ipa)
- 200–280%
- Minimal
- Comparable synergy to Tes+Ipa but CJC's extended half-life complicates dosing adjustments and increases receptor desensitization risk
- GHRP-2
- 20–30 minutes
- 180–220%
- Moderate (40–60% cortisol increase)
- Higher GH amplitude than ipamorelin but significant ACTH/cortisol elevation limits research applicability in metabolic studies
- Sermorelin
- 10–20 minutes
- 100–130%
- Shorter half-life and lower receptor affinity than tesamorelin; requires more frequent dosing for equivalent GH response